Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.

+ Publication-Date Published in the last:

30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years

Or published in the following date range:
From (yyyy/mm/dd - month and day are optional) to ('to' is optional)
+ Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+ Sort-Order
Sort the retrieved articles by:
relevance
publication date
+ Language And with languages:

+ Species
And for:
Humans
Animals
+ Gender
And for:
Male
Female
+ Age And for these age groups:

Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years

+ Title
And for this query matching the titles:
+ Transliterated-Title
And for this query matching the title in original language:
+ Abstract
And for this query matching the abstratcs:
+ Major-Mesh
And for this query matching the MeSH-Major terms:
+ Mesh
And for this query matching any MeSH terms:
+ Journal
And for one or more of these journal abbreviated names:
OR OR
(see title abbreviations)+ Volume
And with journal volume number:
+ Issue
And with journal issue number:
+ Page
And with page number:
+ ISSN
And with ISSN:
+ Publication-Place
And with journal's country of publication:
+ Author

+ Affiliation
And with affiliation to:
+ Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior) + PMID
Show me only articles for these PMIDs (PubMed IDs):

Page Format
Any submit button will submit all of the items you have changed.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lenalidomide therapy in myelofibrosis withmyeloidmetaplasia.

We present results of 2 similarly designed but separate phase 2 studies involving single-agent lenalidomide (CC-5013, Revlimid) in a total of 68 patients with symptomatic myelofibrosis withmyeloidmetaplasia (MMM).

Protocol treatment consisted of oral lenalidomide at 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) for 3 to 4 months with a plan to continue treatment for either 3 or 24 additional months, in case of response.

Additional treatment effects in these patients included resolution of leukoerythroblastosis (4 patients), a decrease in medullary fibrosis and angiogenesis (2 patients), and del(5)(q13q33) cytogenetic remission accompanied by a reduction in JAK2(V617F) mutation burden (1 patient).

We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Thalidomide therapy for myelofibrosis withmyeloidmetaplasia.

METHODS: Forty-four patients who had myelofibrosis withmyeloidmetaplasia received treatment with thalidomide in a Phase II clinical trial at a dose of 200 mg daily with escalation by 200 mg weekly until the best tolerated dose (maximum, 800 mg) was reached.

[Title] Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.

The WHO has recently proposed strict diagnostic criteria for CIMF, and the European consensus for bone marrow fibrosis (BMF) grading recommends 4 classes.

It has been suggested that BMF grading may play a prognostic role in CIMF, but it has never been compared with the other PSSs in the same patients.

We tested a prognostic model for overall survival (OS) based on the WHO criteria and BMF grading in 113 consecutive patients with chronic myeloproliferative disorders (98 with CIMF and 15 with postpolycythemic myelofibrosis), and compared the findings with those of PSSs.

[Title] [Dyspnea secondary to pulmonary hypertension in a patient with splenic myeloidmetaplasia].

There are several possible pathophysiological links between the development of pulmonary hypertension and myelofibrosis with myeloidmetaplasia.

We report a woman with myelofibrosis and myeloidmetaplasia who presented with dyspnea and massive, painful splenomegaly.

Dyspnea in patients with myelofibrosis and myeloidmetaplasia can be secondary to pulmonary hypertension and conversely the differential diagnosis of pulmonary hypertension should include a myeloproliferative syndrome.

The nature of the specific oncogenic mutation(s) is currently being unraveled with the recent discovery of an association between a somatic point mutation of JAK2 tyrosine kinase (V617F) and bcr/abl-negative myeloproliferative disorders, including MMM.

The pathogenetic mechanisms that underlie the secondary bone marrow stromal changes in MMM are also incompletely understood.

Mouse models of this latter disease aspect have been constructed by either in vivo overexpression of thrombopoietin (TPOhigh mice) or megakaryocyte lineage restricted underexpression of the transcription factor GATA-1 (GATA-1low mice).

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pathogenesis of myelofibrosis with myeloidmetaplasia: Insight from mouse models.

Myelofibrosis withmyeloidmetaplasia or idiopathic myelofibrosis is a myeloproliferative disease.

It is known to be a stem-cell disorder that leads to a secondary and reactive stromal reaction in the bone marrow microenvironment that is responsible for impaired haematopoiesis.

Although progress has been made in the elucidation of the pathogenesis of idiopathic myelofibrosis, lack of suitable models has limited our understanding of the pathology.

These insights outline the role of transforming growth factor-beta1 and osteoprotegerin in the promotion of myelofibrosis and osteosclerosis, respectively, paying special regard to the role of abnormal megakaryocyte proliferation and maturation.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Agnogenic myeloidmetaplasia in pregnancy. Case report].

Idiopathic myelofibrosis is a rare myeloproliferative disorder characterized by excessive accumulation of connective tissue in the bone marrow in association with anemia, splenomegaly and extramedullary hematopoiesis.

A rare case of pregnancy in a patient with agnogenic myeloidmetaplasia who carried a term pregnancy is described.

CONCLUSION: Idiopathic myelofibrosis was once thought to be a contraindication to pregnancy.

[Title] Reduced expression of TGF beta1RII in agnogenic myeloidmetaplasia is not due to mutation or methylation.

We have analyzed the factors that could lead to reduced expression of TGF beta1RII in CD34+ cells of AMM patients.

Our results demonstrate absence of mutations in the coding region and the promoter of this gene and absence of CpG methylation of its promoter in AMM patients.

Further studies on transcriptional regulation of TGF beta1RII involving its cis-regulatory elements, the interacting transcription factors and their association with HDAC will provide valuable information on the pathogenesis of AMM and are under current investigation.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Patients (pts) with SCLC, who are refractory to first-line chemotherapy or progress within 3 months (mos) of treatment completion, are less likely to respond to additional chemotherapy and have an expected median survival of 3-5 mos.

The primary endpoint was response rate (ORR, by RECIST), with a goal to demonstrate an ORR ≥18% (point estimate).

RESULTS: In all, 75 pts were enrolled with a median age of 63 years (range 43-88), 52% female, 17% PS 2.

Among those who progressed (2 pts), the median time to disease progression was 7 mos.

At a median length of time of 15 mos., 18 pts. are continuing the therapy with SOR and in all of them the benefit achieved remained unchanged.

However, notwithstanding the rather small sample size of pts., the overall clinical benefit rate (PR+SD) turned out particularly high (> 90%): chiefly, the evidence of a long lasting disease control both for patients achieving partial response and for those with stable disease makes SOR a very useful treatment for patients with mRCC.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963393.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 7057 Background: Nilotinib is a potent and highly selective BCR-ABL inhibitor approved for the treatment of Ph+ CML patients (pts) in chronic phase or AP who are resistant or intolerant to prior therapy including IM.

Cytogenetic responses were also durable with 70% of pts maintaining MCyR at 24 mos; 83% of pts maintained CCyR at 12 mos.

Estimated OS at 24 mos was 67%.

CONCLUSIONS: These long-term follow-up results confirm that nilotinib induces rapid and durable responses in CML-AP pts who failed prior IM due to intolerance or resistance, with a favorable risk/benefit.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961447.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

The primary objective of this study was to determine the proportion of pts treated with bevacizumab on a phase II clinical trial with stable disease by RECIST who demonstrated disease progression (pgrn) as assessed by modified GCIG CA125 criteria.

Primary endpoints of the clinical trial were progression-free (PF) survival at 6 months and response assessed by RECIST criteria.

Pts were removed from therapy/evaluation for disease prgn by RECIST, toxicity, or by subject request.

RESULTS: The median PFS by RECIST was 4.7 mos.

Of those patients who had prgn by CA125, the median residual time to prgn by RECIST was 1.4 mos.

Ten pts who survived PF for at least 6 mos. by RECIST indicated treatment failure before 6 mos. by CA125, or 40% of the 25 positive outcomes.

Eight pts continued to receive treatment for at least 4 mos. after prgn by CA125, with one continuing therapy for more than 3 years.

CONCLUSIONS: Serum CA125 levels were a useful marker of progression in some pts treated on this trial; however, some pts received clinical benefit from continued therapy in spite of indications of disease prgn by CA125.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27960764.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

There was a trend for overall survival and EGFR level at each cutpoint in S0536 but the results did not achieve statistical significance (15 vs 11 mos, p=0.14; 15 vs 11 mos, p=0.20 and 14 mos vs not reached, p=0.10, respectively).

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The primary objective of this study was to describe the demographics, treatment, toxicity, and overall survival (OS) of all patients ≥ 65 years who presented to the Phase I clinical trials service at KCI between 1995-2005.

RESULTS: 216 patients met the study criteria.

66% of patients had a history of cardiovascular disease but renal, liver, hematological diseases were found in less than 7% of patients at baseline.

The median OS for PC, PE, and PT was 3.9 mos, 2.2 mos, and 8.4 mos, respectively (p < 0.001 between any pair).

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961597.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

(2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962920.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Of the 5 melanoma patients one from the 1st schedule showed stable disease and lived for 13.8 months; 3 patients from the 2nd schedule are still alive.

Current mOS for pancreatic carcinoma patients in cohort 1 (N=5) of the 2nd schedule is 13.2 months; 2 of these patients are alive, one with stable disease 14.8 months after begin of trabedersen treatment.

A randomized, active-controlled phase II study compared to standard therapy in patients with pancreatic carcinoma is in preparation; another one in malignant melanoma is being planned.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27964197.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Paclitaxel plus carboplatin (PC) in patients with metastatic melanoma (MM): Experience in a single institution.

: e20019 Background: The number of agents active in patients with metastatic melanoma is limited and cure is not an objective for treatment at this stage, so that clinical benefit in these patients is the most important.

The regimen was weekly paclitaxel (at a dose of 80 mg/m2) received on days 1, 8, and 15 of a 21-day cycle and carboplatin (AUC 5) on day 1.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In a phase III randomized study, sorafenib demonstrated a 2% partial response (PR) rate with a median time to symptomatic progression of 4.1 months (mos) and radiologic progression of 5.5 mos, however patients (pts) had not received prior systemic treatment.

Peri was evaluated in a phase II multi-disease trial where 558 pts were randomized to daily vs. weekly schedules of Peri (50/100 mg daily or 900/1,200 mg weekly) with 42 of the pts having HCC.

[Publication-country] United States

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Value of stable disease (SD) in drug development of targeted therapies (TGT).

Aware the acceptance of SD as a measure of activity led to its being increasingly reported with traditional cytotoxic agents (CTX), we set about to methodically compare the occurrence of SD in phase II trials of TGT and CTX.

Thirty-eight properties including CR, PR, SD, PFS, and OS were recorded for each study.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The primary objective of this analysis was to establish a CAF signature based on a set of individual markers at BL with a significant and differential impact on the association between treatment arm and PFS.

Pts with high OPN benefitted more from single agent SR (7.74 vs. 3.93 mos for the combination; p = 0.007), but no differences were found for those with low OPN.

Lower than median on-treatment increases in sCA9 (D28, p = 0.01) and GRO-alpha (D56, p = 0.04) on SR only were also associated with a better outcome.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27964391.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In a dose finding trial, conducted in our hospital on ITBC patients using C and G with concurrent XRT, after maximum transurethral resection (TUR), the maximum tolerated dose of G was 400 mg/sqm (IJROBP 2003).

We are presenting the long-term clinical outcome of the 16 patients involved in the dose-finding trial, together with that of the 9 pts enrolled in the phase II study.

In dose finding study G was given weekly from 200 to 500 mg/sqm: since unacceptable toxicity was observed in 2 cases (one death for toxicity) at the higher dose level, the recommended G dose for phase II trial was 400 mg/sqm on day 1,8 q 21 for 2 courses together with C and XRT.

A cystoscopic re-evaluation was scheduled 6-8 weeks after treatment.

RESULTS: Except the pt died during treatment for toxicity, all the remaining 24 pts were microscopically disease free at cystoscopic re-evaluation.

Seven local and 2 distant relapses have been observed so far, at a median follow-up of 66 mos.

Presently, 16 pts (67%) is alive and disease-free, with 1 patient died for lung cancer.

All pts alive have retained their bladder, with a normal organ function, in absence of any relevant long-term toxicity.

Considering the 100% of complete response observed, this combination could be of interest to explore a possible enhancement of the disease control of C plus XRT, that is today the treatment of choice in the conservative therapy of ITBC.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963102.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Pts with no progressive disease (evaluated at 12 weeks) continued to receive Sorafenib at the standard dose, while progressive pts received an increasing dose (600 mg BID) with early disease restaging after 4 weeks.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e20005 Background: Uveal melanoma (UM) is a rare disease characterized by an unpredictable course and variable outcome ranging from cure by local treatment to the occurrence of untreatable metastasis.

RESULTS: The med. age at diagnosis of UM was 58 yrs (range 30-94).

MUM was more common in women (F:M ratio 48:28) and independent from the side of the primary tumor (left vs. right eye).

Synchronous metastasis was found in 9% of cases, all others had metachronous disease after a med. interval of 40 mos (range, 7-420).

Statistical analysis failed to identify predisposing factors for MUM with the exception of a significant negative correlation between age at diagnosis of UM and time until metastatic disease (Spearman ρ = -0.4, p<0.001).

OS from diagnosis of UM was 46 mos (range, 2-182), and 4,5 mos after diagnosis of metastasis (range, 1-128).

CONCLUSIONS: In this orphan disease with female predominance metastasis occurs late, is mainly found but not confined to the liver, and is associated with high morbidity, as >1/3 of pts do not qualify for further therapy.

Advances in MUM can only be achieved by networking of sites interested in this tumor with systematic collection of data and tissue to improve our understanding of the molecular biology of the disease.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962598.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.

METHODS: 72 patients (pts) with relapsed/refractory MM received 0.7 - 1.3 mg/m<sup>2</sup> Bz as IVB followed by 1-hr infusion of 100 -340 mg/m<sup>2</sup> Tan on days 1, 4, 8,11 q 21d, with 42 pts receiving the highest dose of both drugs as part of a phase II expansion.

RESULTS: Of 72 pts, 72% had IgG subtype with a median age of 60 yo.

Median time since MM diagnosis was 50 mos with median of 5 (1-15) prior regimens.

58 pts with measurable disease were treated at 1 or 1.3 mg/m<sup>2</sup> Bz.

Median duration of response (DOR) for all pts with response (n=14) was 10.7 mos, including 3 Bz-refractory pts who had durable PR through mos 12, 22 and 28.

3 other pts remain in response through 24 mos.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27960855.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

METHODS: Primary endpoint was major cytogenetic response (MCyR).

Median duration of prior IM treatment was 32 (<1-94) mos.

59% achieved an MCyR (2.8 mos median time to MCyR; 56% in IM-resistant, and 65% in IM-intolerant pts), including 73% of pts with a baseline CHR and 44% achieved a CCyR (41% in IM-resistant; 51% in IM-intolerant pts).

[Publication-country] United States

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: This is a prospective, longitudinal study of low-income, underserved breast cancer survivors who spoke English or Spanish, did not have metastatic disease, and were enrolled in the Medi-Cal Breast and Cervical Cancer Treatment Program.

We interviewed survivors at 6 mos., 18 mos., and 3 yrs. after diagnosis to assess changes in employment status.

The impact of independent variables including ethnicity, employment at diagnosis, job type, age, health status, and education was assessed using chi-square tests.

At diagnosis, 51% of Latinas and 59% of Caucasians were employed (p = 0.07), and among these, Latinas were less likely to be working at 6 and 18 mos. than Caucasians (27% vs. 47% at 6 mos., p = 0.002 and 45% vs. 59% at 18 mos., p = 0.026).

Job type at diagnosis was associated with RTW.

CONCLUSIONS: Employed low-income Latinas and Caucasians appear to follow different RTW trajectories after breast cancer, with fewer Latinas working at 6 and 18 mos.

Differences exist in job type between these populations; Caucasians have greater variation in job type and a trend toward greater likelihood of changing job type after breast cancer.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961765.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

RESULTS: 19 pts were identified with melanoma and concomitant immune suppression in a database of 1820 melanoma pts.

Compared to the database as a whole, cases were more likely to be female (84% vs 45%) and have a higher disease stage (42% stage IIIB/C vs 26%).

In addition, more cases appeared to have an amelanotic primary (21% vs. 5.4%) or an atypical mole syndrome (21% vs 10.2%).

For pts who relapsed, the cases had a shorter disease free interval (DFI) (2.1 vs 9.7 yrs) than the controls.

At a median f/up of 52 mos, 37% of the cases had relapsed and all of these pts had died.

At a median f/up of 76 mos, 30% of the controls had relapsed yet only 47% of these pts had died.

As a consequence, cases appeared more likely to have died of their disease than controls (42% vs 23%) (p=0.10).

CONCLUSIONS: Compared to the general melanoma population, pts with concomitant immune suppression appear more likely to be female, have an amelanotic primary or atypical mole syndrome and more advanced disease at presentation.

Thus, diagnosis and treatment of a primary melanoma at an early stage appears especially important in an immunosuppressed population.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962173.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Title] Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT).

The 6MWT was administered in standardized fashion (American Thoracic Society: observed laps of a 30 - 35 meter long course, indoors, level, without encouragement), and then repeated for further validation.

Cancer 1999) embedded in the MFSAF) showed patients with a higher BFI (i.e., more fatigued) had more impairment in the 6MWT than those with low BFI scores.

Validation of the ability of the 6MWT to measure functional improvements in MF patients as a response to novel therapy trials is planned.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961476.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e16074 Background: The survival benefit of D in treatment of hormone refractory PC (HRPC) has been established in the TAX327 trial, but it is unclear how this benefit would translate in a heterogeneous population.

This study sought to simulate the survival impact of D in a population of older pts with M1 PC on androgen deprivation therapy (ADT).

The simulated benefit was assessed at 12 mos and 24 mos post-diagnosis of M1 PC in SM pts.

Median survival benefit of D was 3.2 mos based on Kaplan-Meier estimates and 2.4 mos using parametric curves in the TAX327 69+ group.

Following covariate-adjustment in the SM sample, at 12 mos post-diagnosis, the median survival in mos was 61.7 (CI 36.3 - 87) in the ADT group and 62 (CI 37.6 - 87.1) in the simulated ADT+D group (i.e., 0.3 mos simulated benefit of D).

A 0.8 mos simulated benefit was found if D was initiated 24 mos post diagnosis (in pts more likely to have HRPC).

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27963046.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

CONCLUSIONS: In this analysis, median OS time for pts with mRCC treated in the modern era with TT without CN is superior to historical experience with IFN- α.Compromised PS, LN involvement, and non-clear cell histology were associated with worse outcome.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962960.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

CONCLUSIONS: Preliminary data prior to unblinding the study treatment arms, from pooled data, suggest that L may be administered > 6 mos with acceptable toxicity, and is associated with PSA declines and long term stabilization in pts with BR.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27964411.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

However, a subset analysis of TRIBUTE pts with a never smoking history suggested that improved survival may occur when the pt population is partially enriched to increase the proportion with an EGFR-TKI induced apoptotic effect (Miller VA.

RESULTS: With a median follow-up of 24 mos, the median TTPs are 21+ mos and 7 mos and the median survivals are 31+ and 12 mos in groups A and B, respectively.

CONCLUSIONS: These data suggest that EGFR-TKI induced apoptosis may act synergistically with concurrent 1<sup>st</sup> line chemotherapy in pts with advanced or metastatic NSCLC and a new paradigm for incorporation of biologically targeted agents into chemotherapy regimens.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27962621.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Relative risk of patients who has a history of radical nephrectomy for RCC treatment was 4.1 (95% CIs, 1.2 to 13.4), and 5.4 (95% CIs, 1.2 to 27.7) for disease-free survival and disease-specific survival, respectively.

Disease-specific survival of 92% at 5-years and 83% at 10-years is possible.

Preceding radical nephrectomy for RCC treatment was the only independent predicting factor for both disease-free and disease-specific survival.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27964294.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: This cross-sectional study utilizes data obtained by surveying physicians of a population-based sample of women with incident breast cancer.

Physicians were queried regarding tumor board attendance, specialty (medical oncologist [MO], radiation oncologist [RO], surgeon indicating that the hospital at which most breast cancer surgeries are performed has an American College of Surgeons accredited program [ACOSSg] and surgeon without such affiliation [non-ACOSSg]), physician characteristics (gender, race, teaching involvement, patient volume, number of offices, ownership interest), and practice setting (practice type, size, reimbursement).

The 65/60 pts were well-balanced for disease characteristics and received a median 3/3.5 cycles per patient (range 1-11/0-17) of C + PLD/PLD, 35 pts (21/14) discontinued study treatment(s) due to the hold, respectively.

Non-hematologic AEs were similar for both arms, except the incidence of Grade 2-3 Palmar-Plantar Erythrodysesthesia (PPE) (9% vs. 21%) and stomatitis (17% vs. 23%) was lower and less severe with C+PLD vs. PLD.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Until recently, tx for pts with progressive, RAI negative disease was limited.

METHODS: Adult pts with a diagnosis of DTC treated with single agent sorafenib (SOR) or sunitinib (SUN), and who had a baseline and at least 1 follow-up (f/u) scan after 3 months (mos) of therapy, were included.

15 pts met inclusion criteria: 9 women, 6 men.

No pts were excluded due to progression or death before 3 mos.

Most patients had RAI negative disease.

Four pts had bone mets: 2 had XRT and had SD in bone, while the other 2 did not have XRT and had PD in bone.

At 12 mos PFS was 65% and OS was 85%.

Median f/u time was 16 mos.

Log (TG) significantly correlated with response to tx and therefore may have value as a surrogate marker of response.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27961926.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: e19513 Background: The outcome of patients with MM relapsing after ASCT used early in the disease course or after failure of initial therapy, is not well defined.

RESULTS: We studied 487 patients who had relapsed following a single ASCT, of whom 351 (72%) had an early SCT (≤ 12 mos from diagnosis).

The median estimated follow up for all patients was 27 mos, 50 mos and 69 mos from relapse, SCT and diagnosis respectively.

The median overall survival (OS) from the time of relapse was 30 mos for the early SCT group and 21 months for the late SCT group.

The median time to relapse following transplant was 15 mos (3-119) among early SCT group and 12 mos (3-76) among the late SCT group.

Among the early group, nearly a third of the patients achieved a PR or better to first salvage therapy (Table), with another third achieving stable disease and 25% of patients did not have response data.

The median progression free survival for the first salvage regimen was 8 mos; 18 mos for those with PR or better and 5 mos for those with SD as the best response.

Those with a durable response to transplant and those not requiring initiation of therapy for long periods after disease relapse have favorable disease biology and have prolonged survival after relapse.

The natural history of the disease provides a valuable benchmark for evaluation of newer treatment approaches.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27960950.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 9599 Background: We have previously identified overall a single-item measure for baseline quality of life (QOL) as a strong prognostic factor for survival (Tan, ASCO 2008), and that fatigue was an important component of patient QOL (Sloan, 2007).

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 557 Background: The Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) examined the efficacy of 3 years (yrs) of treatment with goserelin in combination with ET (anastrozole or tamoxifen) with or without ZOL 4 mg q6 mos in 1,803 premenopausal women with EBC (median age 45 yrs).

After a median follow-up of 47.8 mos (max 84 mos), risk of disease-free survival (DFS) events was reduced by 36% (HR = 0.64; p = 0.01) in patients (pts) who received ZOL (ZOL+ET) compared with those who did not (ET).

A Canadian healthcare system perspective and a lifetime timeframe were used.

[Email]Email this result itemEmail the results to the following email address: [X] Close

(PMID = 27960672.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Our study investigated the efficacy and safety of a biweekly I + C combination in patients (pts) with mCRC.

METHODS: mCRC pts who failed 1st line fluoropyrimidine/oxaliplatin regimens and had not received I or C, were eligible for this open label phase II trial with response rate (RR) as the primary end-point and planned sample size of 31 patients to achieve a 25% RR with 80% power.